健脾益气摄血方调控原发免疫性血小板减少症肠道免疫机制研究  

Study on the Intestinal Immune Mechanism of Jianpi Yiqi Shexue Formula in Regulating Primary Immune Thrombocytopenia

作　　者：黄子明 侯丽[1] 李蕊白 王冲[1] 何昊[2] 杨盼 张雅月[1] HUANG Ziming;HOU Li;LI Ruibai;WANG Chong;HE Hao;YANG Pan;ZHANG Yayue(Hospital Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China;Xi′an Medical University,Xi′an 740000,China)

机构地区：[1]北京中医药大学东直门医院,北京100700 [2]西安医学院,西安710021

出　　处：《世界中医药》2021年第3期381-383,392,共4页World Chinese Medicine

基　　金：国家重点基础研究发展计划(“973”计划)项目(2013CB531705);国家自然科学基金青年科学基金项目(81703903)。

摘　　要：原发免疫性血小板减少症(ITP)是一种以血小板减少为特征的自身免疫性疾病,其发病机制、发病原因目前尚未完全明确。ITP的中医病名为“紫癜病”。陈信义教授团队认为ITP的病机为“脾气亏虚、脾不统血”,拟定健脾益气摄血方,临床上取得良好疗效。并为此开展一系列临床和基础研究证实其免疫调控效果,以期阐明其具体起效机制。文章就陈信义教授在开展国家重点基础研究发展计划(“973”计划)项目临床试验过程中对健脾益气摄血方治疗ITP研究所采用的免疫指标进行概括和讨论。Immune thrombocytopenia(ITP)is an autoimmune disease characterized by thrombocytopenia,and its pathogenesis and causes have not been completely clarified.ITP′s TCM disease is called“purpura”.Professor CHEN Xinyi′s team thinks that the pathogenesis of ITP is“spleen deficiency and spleen not controlling blood”,so Jianpi Yiqi Shexue Formula has achieved good clinical effect.For this reason,a series of clinical and basic studies have been carried out to confirm its immunomodulatory effect,so as to clarify its specific mechanism.In this paper,Professor CHEN Xinyi summarized and discussed the immune indexes adopted by Jianpi Yiqi Shexue Formula in treating ITP research during the clinical trial of the National Key Basic Research Development Program(“973”Program).

关 键 词：健脾益气摄血方 原发免疫性血小板减少症 免疫 

分 类 号：R242[医药卫生—中医临床基础]